New Releases from NCBI BookshelfInavolisib (Itovebi): Indication: Inavolisib in combination with palbociclib and fulvestrant is indicated for the treatment of adult patients with endocrine resistant, PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment: Reimbursement Recommendation [Internet].Inavolisib (Itovebi): Indication: Inavolisib in combination with palbociclib and fulvestrant is indicated for the treatment of adult patients with endocrine resistant, PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment: Reimbursement Recommendation [Internet].
